Business Context and Reporting Period
This Form 8-K was filed by Akebia Therapeutics, Inc. on January 4, 2016, reporting a corporate event that occurred on the same date. The filing addresses the termination of a material definitive agreement regarding equity financing.
Key Financial Metrics
This filing does not report standard financial performance metrics such as revenue, profit, cash flow, or margins. The only financial data provided relates to the terminated equity offering:
- Total Authorized Offering: $50 million
- Amount Sold Prior to Termination: Approximately $18.8 million
- Remaining Capacity: Approximately $31.2 million (no longer available)
Material Changes
On January 4, 2016, the Company terminated its Controlled Equity Offering SM Sales Agreement with Cantor Fitzgerald & Co., which was originally dated August 11, 2015. As a result of this termination, no additional shares of common stock will be sold under this specific agreement.
Outlook, Risks, and Management Commentary
The filing contains no forward-looking guidance, management commentary on future operations, or discussion of risks beyond the immediate cessation of the sales agreement. The document serves strictly as a notification of the contract termination.
Key Facts for Investor Verification
- Verify the current cash position of Akebia Therapeutics, Inc. to assess the impact of halting the remaining $31.2 million in potential capital raises.
- Confirm whether the Company has initiated alternative financing strategies to replace the terminated Sales Agreement.
- Review the original August 11, 2015, Form 8-K (Exhibit 1.1) for the full terms of the terminated agreement.